Senators held a live confirmation hearing for Heidi Overton, the nominee to become the U.S. Food and Drug Administration’s commissioner. Overton, known for her outspoken criticism of abortion, will be responsible for overseeing the agency’s ongoing review of mifepristone, the nation’s leading abortion pill.
The hearing, broadcast by PBS NewsHour, focused on Overton’s record and her views on reproductive health policy. Senators questioned her about how she would balance her personal stance with the FDA’s mandate to evaluate medical products based on safety and efficacy.
Mifepristone, often used in combination with misoprostol, is a medication that terminates early pregnancies. Its approval and regulation have become a focal point of the national debate over abortion rights.
Overton’s nomination follows a broader effort to shape the FDA’s approach to reproductive health. Her appointment would place her at the centre of the agency’s regulatory decisions on mifepristone and other related products.
<small>Source: PBS NewsHour — read the original story there.</small>
